The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Open accessAbstract
PURPOSE: The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). Because The Cancer Genome Atlas defined an EC molecular classification with strong prognostic value, we investigated prognosis and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants. METHODS: Paraffin-embedded tissues of 423 consenting patients were collected. Immunohistochemistry for p53 and mismatch repair (MMR) proteins, and DNA sequencing for POLE exonuclease domain were done to classify tumors as p53 abnormal (p53abn), POLE-ultramutated ( POLEmut), MMR-deficient (MMRd), or no specific molecular profile (NSMP). The primary end point was recurrence-free survival (RFS). Kaplan-Meier method, log-rank test, and Cox model were used for analysis. RESULTS: Molecular analysis was successful in 410 high-risk EC (97%), identifying the 4 subgroups: p53abn EC (n = 93; 23%), POLEmut (n = 51; 12%), MMRd (n = 137; 33%), and NSMP (n = 129; 32%). Five-year RFS was 48% for patients with p53abn EC, 98% for POLEmut EC, 72% for MMRd EC, and 74% for NSMP EC ( P < .001). The 5-year RFS with CTRT versus RT for p53abn EC was 59% versus 36% ( P = .019); 100% versus 97% for patients with POLEmut EC ( P = .637); 68% versus 76% ( P = .428) for MMRd EC; and 80% versus 68% ( P = .243) for NSMP EC. CONCLUSION: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLEmut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as well as in future trials to target specific subgroups of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S., Yang, W., Lum, A., Senz, J., Boyd, N., Pike, J., Anglesio, M., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 975
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
Stelloo, E., Nout, R. A., Osse, E. M., Jürgenliemk-Schulz, I. J., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 846
Self-citationKommoss, S., McConechy, M. K., Kommoss, F., Leung, S., Bunz, A., Magrill, J., Britton, H., Kommoss, F., Grevenkamp, F., Karnezis, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy058 · Cited by 776
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30079-2 · Cited by 641
Self-citationFader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L., O’Malley, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5966 · Cited by 516
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., D'Amico, R., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30395-x · Cited by 457
Self-citationClinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas
León‐Castillo, A., Gilvazquez, E., Nout, R., Smit, V. T., McAlpine, J. N., McConechy, M., Kommoss, S., Brucker, S. Y., Carlson, J. W., Epstein, E., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5373 · Cited by 415
Self-citationInterpretation of somatic POLE mutations in endometrial carcinoma
León‐Castillo, A., Britton, H., McConechy, M. K., McAlpine, J. N., Nout, R., Kommoss, S., Brucker, S. Y., Carlson, J. W., Epstein, E., Rau, T. T., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5372 · Cited by 409
Self-citationPoor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
Gilks, C. B., Oliva, E., & Soslow, R. A. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f576a · Cited by 401
A panoply of errors: polymerase proofreading domain mutations in cancer
Rayner, E., van Gool, I. C., Palles, C., Kearsey, S. E., Bosse, T., Tomlinson, I., & Church, D. N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.12 · Cited by 373
Self-citationPractical guidance for mismatch repair-deficiency testing in endometrial cancer
Stelloo, E., Jansen, A. M. L., Osse, E. M., Nout, R. A., Creutzberg, C. L., Ruano, D., Church, D. N., Morreau, H., Smit, V. T. H. B. M., van Wezel, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw542 · Cited by 342
Self-citationRandall, M. E., Filiaci, V. L., McMeekin, D. S., von Gruenigen, V., Huang, H. Q., Yashar, C. M., Mannel, R. S., Kim, J., Salani, R., DiSilvestro, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01575 · Cited by 336
Kurnit, K. C., Kim, G. N., Fellman, B. M., Urbauer, D. L., Mills, G. B., Zhang, W., & Broaddus, R. R. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.15 · Cited by 325
Singh, N., Piskorz, A. M., Bosse, T., Jimenez‐Linan, M., Rous, B., Brenton, J. D., Gilks, C. B., & Köbel, M. (2020) · The Journal of Pathology · doi:10.1002/path.5375 · Cited by 316
Self-citationIncorporation of molecular characteristics into endometrial cancer management
Vermij, L., Smit, V., Nout, R., & Bosse, T. (2020) · Histopathology · doi:10.1111/his.14015 · Cited by 291
Self-citationFrequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
de Jonge, M. M., Auguste, A., van Wijk, L. M., Schouten, P. C., Meijers, M., ter Haar, N. T., Smit, V. T. H. B. M., Nout, R. A., Glaire, M. A., Church, D. N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1443 · Cited by 199
Self-citationGong, J., Le, T. Q., Massarelli, E., Hendifar, A. E., & Tuli, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0361-7 · Cited by 191
Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
McConechy, M. K., Talhouk, A., Leung, S., Chiu, D., Yang, W., Senz, J., Reha-Krantz, L. J., Lee, C.-H., Huntsman, D. G., Gilks, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2233 · Cited by 190
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30120-6 · Cited by 178
Self-citationHER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
Buza, N., Roque, D. M., & Santin, A. D. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0416-ra · Cited by 160
Just how accurate are the major risk stratification systems for early-stage endometrial cancer?
Bendifallah, S., Canlorbe, G., Collinet, P., Arsène, E., Huguet, F., Coutant, C., Hudry, D., Graesslin, O., Raimond, É., Touboul, C., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.35 · Cited by 140
Reijnen, C., Küsters‐Vandevelde, H. V. N., Prinsen, C., Massuger, L. F. A. G., Snijders, M. P. M. L., Kommoss, S., Brucker, S. Y., Kwon, J. S., McAlpine, J. N., & Pijnenborg, J. M. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.03.097 · Cited by 96
van Gool, I. C., Rayner, E., Osse, E. M., Nout, R. A., Creutzberg, C. L., Tomlinson, I. P. M., Church, D. N., Smit, V. T. H. B. M., de Wind, N., Bosse, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0266 · Cited by 74
Self-citationvan Eijk, R., Stevens, L., Morreau, H. M., & van Wezel, T. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.06.004 · Cited by 73
Germline BRCA -Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
de Jonge, M. M., Ritterhouse, L. L., de Kroon, C. D., Vreeswijk, M. P. G., Segal, J. P., Puranik, R., Hollema, H., Rookus, M. A., van Asperen, C. J., van Leeuwen, F. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0848 · Cited by 54
Self-citationSarı, A., Pollett, A. F., Eiriksson, L. R., Lumsden-Johanson, B., de Laar, E. V., Kazerouni, H., Salehi, A., Sur, M., Lytwyn, A., & Ferguson, S. E. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001220 · Cited by 38
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Self-citationCrosbie, E. J., Kitson, S. J., McAlpine, J. N., Mukhopadhyay, A., Powell, M. E., & Singh, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00323-3 · Cited by 1,333
Self-citationFIGO staging of endometrial cancer: 2023
Berek, J. S., Matias‐Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., Concin, N., & Endometrial Cancer Staging Subcommittee, F. W. C. C. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14923 · Cited by 1,000
Self-citationMakker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Self-citationLu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Metadata
- Authors
- León-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., Fyles, A., Haie-Meder, C., Smit, V. T. H. B. M., Edmondson, R. J., Putter, H., Kitchener, H. C., Crosbie, E. J., de Bruyn, M., Nout, R. A., Horeweg, N., Creutzberg, C. L., Bosse, T., & on behalf of the TransPORTEC consortium
- Venue
- Journal of Clinical Oncology
- Published
- 2020-10-10
- Volume
- 38
- Issue
- 29
- Pages
- 3388-3397
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3047152751
- Cited by
- 855
- References
- 29
- FWCI
- 52.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.